Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus ATRIDOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus ATRIDOX.
ACTICLATE CAP vs ATRIDOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic